Nöromusküler Hastalıklarda Değerlendirme Testleri
Özet
Nöromusküler hastalıklar; ön boynuz motor nöron, periferal sinir, kas-sinir kavşağı ve kası etkileyen süreçleri kapsar. Özellikle DMD ve SMA gibi hastalıklarda gen tedavilerinin artmasıyla birlikte, tedavi etkinliğini belirlemek adına değerlendirme testlerine duyulan ihtiyaç kritik düzeyde yükselmiştir. Bu çalışma, çocukluk çağında sık görülen SMA, DMD ve Charcot-Marie-Tooth (CMT) hastalarının klinik takibinde kullanılan spesifik ve fonksiyonel değerlendirme ölçeklerini detaylandırmaktadır. Bu testler, hastaların fonksiyonel seviyelerini objektif bir şekilde izlemek ve tedavi yanıtlarını ölçmek amacıyla etkin biçimde kullanılmaktadır.
Neuromuscular diseases involve pathologies affecting motor neurons, peripheral nerves, neuromuscular junctions, and muscles themselves. The emergence of new clinical treatments, particularly gene therapies for Duchenne muscular dystrophy (DMD) and Spinal muscular atrophy (SMA), has significantly heightened the necessity for standardized assessment tools to measure treatment efficacy. This review examines critical evaluation scales utilized in pediatric care for SMA, DMD, and Charcot-Marie-Tooth (CMT) disease. These assessment methods provide objective data on motor function and patient progress, serving as essential instruments for clinical decision-making and patient monitoring.
Referanslar
Cano SJ, Mayhew A, Glanzman AM, et al. Rasch analysis of clinical outcome measures in spinal muscular atrophy. Muscle Nerve. 2014;49(3):422-30.
Hobart JC, Cano SJ, Zajicek JP, Thompson AJ. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol. 2007 Dec;6(12):1094-105.
Montes J, Gordon AM, Pandya S, De Vivo DC, Kaufman P. Clinical Outcome Measures in Spinal Musculer Atrophy. J Child Neurol 2009;24:968.
Piper MC, Pinnell LE, Darrah J, Maguire T, Byrne PJ. Construction and validation of the Alberta Infant Motor Scale (AIMS). Can J Public Health 1992;83(2):46-50.
Campbell SK, Kolobe TH, Wright BD, Linacre JM. Validity of the Test of Infant Motor Performance for prediction of 6-, 9- and 12-month scores on the Alberta Infant Motor Scale. Dev Med Child Neurol 2002;44:263-72.
Glanzman AM, Mazzone E, Main M, et al. The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord. 2010 Mar;20(3):155-61.
Campbell SK. The test of infant motor performance: test user’s manual, version 2.0: a training manual. Chicago: Infant Motor Performance Scales; 2005.
Folio MR, Fewell RR. Peabody developmental motor scales. 2. Austin: PRO-ED; 2000.
Garin O. Ceiling Effect. Michalos A.C, editor. Encyclopedia of Quality of Life and Well-Being Research. 2014 Edition. Dordrecht, Springer. p. 631-33.
Glanzman AM, McDermott MP, Montes J, et. al; Pediatric Neuromuscular Clinical Research Network for Spinal Muscular Atrophy (PNCR); Muscle Study Group (MSG). Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Pediatr Phys Ther. 2011;23(4):322-6.
O’Hagen J. An expanded version of the Hammersmith functional motor scale for SMA II and III patients. Neuromuscul Disord. 2007;17:693–7.
Brazelton TB, Nugent JK. The neonatal behavioral assessment scale. Cambridge: Mac Keith Press; 1995.
Main M, Kairon H, Mercuri E, Muntoni F. The Hammersmith Functional Motor Scale for Children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol. 2003;7:155–59.
Mercuri E, Messina S, Battini R, et al. Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study. Neuromuscul Disord. 2006;16:93–98.
Tiziano, FD, Bertini, E, Messina, S. The Hammersmith functional score correlates with the SMN2 copy number: a multicentric study. Neuromuscul Disord. 2007;17(5):400–3.
Krosschell K, Maczulski J, Crawford T, Scott C, Swoboda K. A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul Disord. 2006;16:417–26.
Krosschell K, Scott C, Maczulski J, et al. Reliability of the Modified Hammersmith Functional Motor Scale in young children with spinal muscular atrophy. Muscle Nerve. 2011;44:246–51.
Kaufmann, P, Muntoni, F. Issues in SMA clinical trial design. The International Coordinating Committee (ICC) for SMA Subcommittee on SMA Clinical Trial Design. Neuromuscul Disord. 2007;17(6):499–505.
Glanzman A, O’Hagen J, McDermott M, et al. Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III. J Child Neurol. 2011;26:1499–1507.
Russell DJ, Rosenbaum PL, Cadman DT, Gowland C, Hardy S, Jarvis S. The gross motor function measure: a means to evaluate the effects of physical therapy. Dev Med Chil Neurol, 1989;31(3):341-52.
Palisano RJ, Hanna SE, Rosenbaum PL, et al. Validation of a model of gross motor function for children with cerebral palsy. Phys Ther. 2000;80(10):974-85.
Rosenbaum PL, Walter SD, Hanna SE, et al. Prognosis for gross motor function in cerebral palsy: creation of motor development curves. J Am Med Assoc, 2002;288(11):1357-63.
McCarthy ML, Silberstein CE, Atkins EA, Harryman SE, Sponseller PD, Hadley-Miller NA. Comparing reliability and validity of pediatric instruments for measuring health and well-being of children with spastic cerebral palsy. Dev Med Child Neurol, 2002;44(7):468-76.
Russell DJ, Avery LM, Rosenbaum PL, Raina PS, Walter SD, Palisano RJ. Improved scaling of the gross motor function measure for children with cerebral palsy: evidence of reliability and validity. Phys Ther, 2000;80(9):873-85.
Fattal-Valevski A, Giladi N, Domanievitz D, et al. Parameters for predicting favorable responses to botulinum toxin in children with cerebral palsy. J Child Neurol, 2002;17(4):272-7.
Iannaccone ST, Hynan LS, American Spinal Muscular Atrophy Randomized Trials (AmSMART) Group. Reliability of four outcome measures in pediatric spinal muscular atrophy. Arch Neurol, 2003;60(8):1130-6.
Nelson L, Owens H, Hynan L, Iannaccone S, AmSMART Group. The gross motor function measure is a valid and sensitive outcome measure for spinal muscular atrophy. Neuromuscul Disord. 2006;16:374–80.
Williams KS, Young DK, Burke GAA, Fountain DM. Comparing the WeeFIM and PEDI in neurorehabilitation for children with acquired brain injury: A systematic review. Dev Neurorehabil. 2017 Oct;20(7):443-451.
Steffensen BF, Lyager S, Werge B, Rahbek J, Mattsson E. Physical capacity in non-ambulatory people with Duchenne muscular dystrophy or spinal muscular atrophy: a longitudinal study. Dev Med Child Neurol. 2002;44(9):623-32.
Alemdaroğlu İ, Karaduman A, İyigün-Yatar G, Tunca-Yılmaz Ö, Topaloğlu H. Turkish version of the Egen Klassifikation scale version 2: validity and reliability in the Turkish population. Turk J Pediatr. 2014;56(6):643-50.
Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981;4(3):186-97.
Angelini C, Pegoraro E, Turella E, Intino MT, Pini A, Costa C. Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve. 1994;17(4):386-91.
Chris K. Observational Gait Analysis (Clinical Gait Analysis Theory and Practise). Elsevier Churchill Livingston Pubs 2006;2(14):145-90.
Mazzone ES, Messina S, Vasco G, et al. Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord. 2009;19(7):458-61.
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-17.
Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-Liduronidase (laronidase). J Pediatr 2004;144:581-88.
Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006;8:465-73.
Laforet P, Clemens PR, Corzo D, et al. Safety and efficacy results from a randomized, double-blind, placebo-controlled study of alglucosidase alfa for the treatment of Pompe disease in juveniles and adults. Neuromuscul Disord 2008;18:832.
Kierkegaard M, Tollback A. Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophy. Neuromuscul Disord 2007;17:943-49.
Harb A, Kishner S. Modified Ashworth Scale. 2021 May 9. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan.
Beals TC, Nickisch F. Charcot-Marie-Tooth disease and the cavovarus foot. Foot Ankle Clin. 2008;13(2):259-74.
Scott E, Mawson SJ. Measurement in Duchenne muscular dystrophy: considerations in the development of a neuromuscular assessment tool. Dev Med Child Neurol. 2006;48(6):540-4.
Estilow T, Glanzman AM, Burns J, et al; CMTPedS STUDY GROUP. Balance impairment in pediatric charcot-marie-tooth disease. Muscle Nerve. 2019;60(3):242-49
Franjoine MR, Gunther JS, Taylor MJ. Pediatric balance scale: a modified version of the berg balance scale for the school-age child with mild to moderate motor impairment. Pediatr Phys Ther. 2003;15(2):114-28.
